USANA Health Sciences, Inc. revised earnings guidance for the year 2023. The company narrows fiscal year 2023 net sales and diluted EPS outlook to $900 million to $920 million and $2.80 to $3.05, respectively (previously $900 million to $950 million and $2.65 to $3.30).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.78 USD | +2.48% | +4.43% | -8.99% |
May. 07 | DA Davidson Adjusts Price Target on USANA Health Sciences to $46 From $48, Maintains Neutral Rating | MT |
May. 01 | Transcript : USANA Health Sciences, Inc., Q1 2024 Earnings Call, May 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.99% | 907M | |
+4.94% | 7.59B | |
-0.05% | 6.07B | |
-4.67% | 3.85B | |
-11.92% | 3.55B | |
-10.53% | 1.28B | |
-31.91% | 1.03B | |
+14.51% | 971M | |
-14.69% | 813M | |
+2.24% | 731M |
- Stock Market
- Equities
- USNA Stock
- News USANA Health Sciences, Inc.
- USANA Health Sciences, Inc. Revises Earnings Guidance for the Year 2023